cagrilintidesemaglutide marketed cagrisema combination cagrilintide dual amylin calcitonin receptor agonist semaglutide agonist injected weekly tested type diabetes obesity preliminary trial results found greater weight loss compared either medication alone significantly improved compared cagrilintide alone nonsignificantly better semaglutide phase ii trial weight loss averaged percent weeks making cagrisema comparable efficacy future trial sponsored novo nordisk comparing tirzepatide cagrisema cagrisema phase iii httpsenwikipediaorgwikicagrilintidesemaglutide